[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-resection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-resection":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,75,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100648706","feasibility-assessment-of-a-medical-device-for-tumour-cell-retention-and-radiotherapy-sensitization-in-patients-with-suspected-high-grade-glioma-100648706",false,"NCT07725640","Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma","CT-GlioHook","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent prior to the performance of any study-specific procedures.\n2. Age ≥18 and \\\u003C70 years at the time of consent.\n3. Suspected newly diagnosed unifocal high-grade glioma, as suggested by preoperative MRI imaging.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n5. Supratentorial and\u002For lobar tumor mass with a volume of less than 60cm3 as assessed by preoperative MRI.\n6. Patient scheduled to undergo surgical resection of the target brain lesion, with an expected extent of resection (EOR) ≥90% based on preoperative imaging and surgical planning and according to the investigator's criteria. The anticipated EOR should be verified intraoperatively using a validated available method depending on availability at study site, such as 5-aminolevulinic acid (5-ALA) fluorescence guidance, ultrasound, or MRI.\n7. Candidate to receive standard-of-care treatment for newly diagnosed glioblastoma, according to current clinical practice and the investigator's judgment.\n8. Able to undergo contrast-enhanced MRI.\n9. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and study procedures and accessible for follow-up after completion of study treatment.\n10. For women of childbearing potential (WOCBP):\n\n    * Must have a negative serum or urine pregnancy test within 7 days prior to inclusion.\n    * Must not be pregnant or breastfeeding at the time of inclusion.\n    * Must agree to use a highly effective method of contraception during the entire study participation period and for at least 6 months after the last dose of temozolomide.\n11. Male and female patients of reproductive potential must agree to use highly effective contraceptive methods.\n\nExclusion Criteria:\n\n1. Life expectancy \\\u003C3 months, as estimated by the investigator.\n2. Surgical resection cannot be assured or is considered not feasible or unsafe based on preoperative assessment.\n3. Tumor located in the posterior fossa or involving critical subcortical structures (e.g., midbrain, brainstem, ventricles, or basal ganglia), where safe surgical resection cannot be achieved.\n4. Presence of multifocal, bilateral, or recurrent tumor, or prior diagnosis of glioblastoma or other intracranial malignancy.\n5. Extent of tumor resection \\\u003C90%. The EOR should be verified intraoperatively using a validated available method depending on availability at study site, such as 5-aminolevulinic acid (5-ALA) fluorescence guidance, ultrasound, or MRI. However, it is up to the neurosurgeon to assess, after reviewing the available data and the resection itself, whether the patient meets the criteria for implantation.\n6. Significant active or uncontrolled concurrent medical conditions, including but not limited to:\n\n   * Active infection requiring systemic therapy,\n   * Symptomatic congestive heart failure,\n   * Unstable angina pectoris,\n   * Clinically significant cardiac arrhythmia,\n   * Uncontrolled hypertension,\n   * Severe pulmonary, hepatic, or renal disease,\n   * Psychiatric or social conditions that, in the opinion of the investigator, would interfere with study compliance or follow-up.\n   * Severe blood clotting disorders\n7. Known hypersensitivity to bovine-derived collagen or other components of the medical device.\n8. Contraindication to contrast-enhanced MRI, including known allergy to gadolinium or presence of non-MRI-compatible implants.\n9. Contraindication to receive radiotherapy or temozolomide, including prior cranial irradiation exceeding safe cumulative dose limits.\n10. Participation in another interventional clinical trial or use of an investigational product within 30 days prior to inclusion, or planned participation during this clinical investigation.\n11. Women who are pregnant or breastfeeding.\n12. Men or women of reproductive potential unwilling to use adequate contraception, as defined in the inclusion criteria.\n13. Inability or unwillingness to comply with clinical investigation procedures, follow-up schedule, or CIP requirements, as judged by the investigator.","ALL","18 Years","70 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, multicenter, single-arm, pilot clinical investigation, aimed at evaluating the safety and preliminary efficacy of the GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment.\n\nGlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins, decreasing infiltration and focalizing the disease, while improving the effects of radiotherapy. Once implanted, GlioHook exerts a dual mechanism that combines tumour cell focalization and radiosensitization.",[27,28,29],"Glioma","High-Grade Glioma (HGG)","Surgical Resection",[31,32,33,34],"Implant","High-Grade Glioma","Radiotherapy","Temozolomide","NOT_YET_RECRUITING","2026-07-24",{"date":38,"type":39},"2026-07-27","ACTUAL",{"date":41,"type":21},"2026-10-30",{"date":43,"type":21},"2028-10-30",{"name":45,"class":46},"Batea Oncology","INDUSTRY",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100558176","primary-tumor-resection-for-m1a-stage-lung-cancer-100558176","NCT06547710","Primary Tumor Resection for M1a Stage Lung Cancer","Primary Tumor Resection for M1a Stage Lung Cancer With Occult Pleural Dissemination Discovered During Surgery: a Prospective, Single-arm, Multi-center, Phase Ⅱ Trial","ECTOP-1023","Inclusion Criteria:\n\n1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;\n2. Aged 18-80 years (including critical values) when signing the informed consent form;\n3. ECOG score 0 or 1;\n4. No previous lung cancer surgery;\n5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;\n6. Occult pleural metastasis found during surgery;\n7. First-time treatment and no radiotherapy or chemotherapy.\n\nExclusion Criteria:\n\n1. The lesion cannot be completely removed surgically;\n2. Cytological or histological pathology confirms other lung malignancies other than lung cancer;\n3. Patients who have undergone lung cancer surgery before;\n4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.","75 Years",{"count":58,"type":21},66,"OBSERVATIONAL","This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.",[62,29],"Lung Cancer Metastatic","RECRUITING","2026-07-05",{"date":66,"type":39},"2026-07-08",{"date":68,"type":39},"2024-04-01",{"date":70,"type":21},"2027-12",{"name":72,"class":73},"Fudan University","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":74},"100570637","meningioma-and-embolism-thrombosis-risk--investigation-of-coagulation-100570637","NCT06709833","Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation","001_2024_BO2","Inclusion Criteria:\n\n* Patients undergoing resection for meningioma or\n* Patients undergoing resection for glioma or\n* Healthy controls\n* written consent for study participation\n\nExclusion Criteria:\n\n\\-",true,{"count":84,"type":21},100,"Despite being generally benign tumors, meningiomas are associated with an increased risk for thrombembolic complications after surgical resection. The molecular mechanisms underlying this circumstance are still unknown.\n\nIn this prospective observational trial, the investigators aim to evaluate the changes in coagulation and platelet function caused by tumor resection.\n\nBlood samples are obtained by patients undergoing meningioma resection before and immediately after resection to detect said changes.\n\nAs a control cohort, blood samples are obtained from patients undergoing resection for glioma.",[87,88,29],"Meningeoma","Thrombembolism",[90,91,92],"meningeoma","thrombembolism","tissue-factor","2025-01-03",{"date":95,"type":39},"2025-01-06",{"date":97,"type":39},"2024-12-16",{"date":99,"type":21},"2026-08-31",{"name":101,"class":73},"University Hospital Tuebingen",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":127},"100201423","phase-2-safety-and-efficacy-study-using-5-ala-oral-administration-as-an-adjuvant-therapy-on-the-rate-of-local-tumor-recurrence-in-patients-who-have-desmoids-tumors-100201423","NCT01898416","Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors","A PHASE 2, SINGLE CENTRE, SINGLE ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 5- ALA POHOTODYNAMIC THERAPY AS ADJUVANT THERAPY AFTER SURGICAL DISSECTION IN PATIENTS WITH DESMOID TUMORS.","Inclusion Criteria:\n\n1. Patient has a resectable histologically confirmed desmoid tumor.\n2. Previously treated (by chemotherapy, irradiation or surgery) patients are eligible.\n3. Age \\> 18 years\n4. Signed informed consent prior to patient recruitment. -\n\nExclusion Criteria:\n\n1. Hepatic enzymes or bilirubin \\> 2X upper limit of normal.\n2. Serum creatinine \\> 2.5 x upper limit of normal.\n3. Suspected \u002Fdocumented metastatic disease.\n4. Active or uncontrolled infections.\n5. Active second malignant disease (excluding non-melanoma skin cancer, or in situ cervix or breast carcinoma) \\\u003C 2 years prior to the study.\n6. Use of other investigational agents \\\u003C 30 days prior to the study.\n7. Patients who are mentally or physically unable to comply with all aspects of the study.\n8. Any serious medical condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he or she participates in this study or confounds the experimental ability to interpret data from the study.\n9. Pregnant or lactating females.\n10. Known intolerance or allergy to 5-ALA\n11. Suspicious or documented acute or chronic porphyria",{"count":110,"type":21},140,[112],"PHASE2","The purpose of this study is to evaluate the efficacy of preoperative 5-ALA oral administration and subsequently intraoperative tumor bed phototherapy with red light laser, as an adjuvant therapy on the 3 years rate of local tumor recurrence in patients with desmoid tumors. To evaluate the Safety of 5-ALA administration. 5 years local recurrence rate.",[115,116,29],"The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an","Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After","2013-10-30",{"date":119,"type":21},"2013-10-31",{"date":121,"type":4},"2013-06",{"date":123,"type":21},"2026-12",{"name":125,"class":126},"michal roll","OTHER_GOV",2]